{name}
{subtitle}
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~42 mi. (Saint-Quentin, France, +226 more cities)
facility
C.H. de Saint Quentin ( Site 0481)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
city
~42 mi. (Saint-Quentin, France, +122 more cities)
facility
C.H. de Saint Quentin ( Site 1111)
drug
etoposide, +5 more drugs
drug type
chemotherapy, +3 more types
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
city
~57 mi. (Reims, France, +8 more cities)
facility
Hôpital Robert Debré, +1 more facility
drug
irinotecan, +1 more drug
drug type
chemotherapy, +1 more type
Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure
city
~57 mi. (Reims, France, +7 more cities)
facility
CHU de Reims
drug
lenvatinib, +1 more drug
drug type
Other, +1 more type
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy
city
~60 mi. (Paris Campagne, France, +55 more cities)
facility
Hôpital Universitaire Pitié Salpêtrière (Adults only)
drug type
cellular therapy, +1 more type
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
city
~60 mi. (Paris Campagne, France, +26 more cities)
facility
Institut Curie /ID# 225829
condition
Malignant Solid Tumor, +1 more condition
drug
ABBV-637, +2 more drugs
drug type
chemotherapy, +1 more type
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
city
~60 mi. (Paris Campagne, France, +24 more cities)
facility
Institut Curie /ID# 223475
biomarker
ER Negative, +2 more biomarkers
condition
Breast Adenocarcinoma, +2 more conditions
drug
ABBV-368, +5 more drugs
drug type
chemotherapy, +1 more type